bevacizumab + gemcitabine + erlotinib

**bevacizumab + gemcitabine + erlotinib** is an investigational combination regimen used in oncology clinical trials, most notably for the treatment of metastatic pancreatic adenocarcinoma. - **Bevacizumab** is a monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), preventing tumor angiogenesis. - **Gemcitabine** is a nucleoside analog (antimetabolite) that interferes with DNA synthesis, resulting in cytotoxic effects on rapidly dividing tumor cells. - **Erlotinib** is a small-molecule inhibitor targeting the epidermal growth factor receptor (EGFR) tyrosine kinase, thereby blocking EGFR signaling involved in cellular proliferation and survival. This triple combination has been evaluated in Phase II/III trials for pancreatic cancer, but has not demonstrated a statistically significant overall survival benefit over gemcitabine and erlotinib, though it improved progression-free survival. Each drug has established mechanisms and safety profiles, and the combination was found to be tolerable in studies[1][3].